Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer

Abstract Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ryoichi Katsube, Kazuhiro Noma, Toshiaki Ohara, Noriyuki Nishiwaki, Teruki Kobayashi, Satoshi Komoto, Hiroaki Sato, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/edf5fed397e64f0e8fa9e8ebc6976513
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:edf5fed397e64f0e8fa9e8ebc6976513
record_format dspace
spelling oai:doaj.org-article:edf5fed397e64f0e8fa9e8ebc69765132021-12-02T11:50:40ZFibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer10.1038/s41598-021-81465-42045-2322https://doaj.org/article/edf5fed397e64f0e8fa9e8ebc69765132021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81465-4https://doaj.org/toc/2045-2322Abstract Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate. We developed fibroblast activation protein (FAP)-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target CAFs (CAFs-targeted NIR-PIT: CAFs-PIT). Thus, we hypothesized that the control of CAFs could overcome the resistance to conventional chemotherapy in esophageal cancer (EC). In this study, we evaluated whether EC cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy are mediated by CAFs. Next, we assessed whether the resistance could be rescued by eliminating CAF stimulation by CAFs-PIT in vitro and in vivo. Cancer cells acquired chemoradiotherapy resistance via CAF stimulation in vitro and 5-fluorouracil (FU) resistance in CAF-coinoculated tumor models in vivo. CAF stimulation promoted the migration/invasion of cancer cells and a stem-like phenotype in vitro, which were rescued by elimination of CAF stimulation. CAFs-PIT had a highly selective effect on CAFs in vitro. Finally, CAF elimination by CAFs-PIT in vivo demonstrated that the combination of 5-FU and NIR-PIT succeeded in producing 70.9% tumor reduction, while 5-FU alone achieved only 13.3% reduction, suggesting the recovery of 5-FU sensitivity in CAF-rich tumors. In conclusion, CAFs-PIT could overcome therapeutic resistance via CAF elimination. The combined use of novel targeted CAFs-PIT with conventional anticancer treatments can be expected to provide a more effective and sensible treatment strategy.Ryoichi KatsubeKazuhiro NomaToshiaki OharaNoriyuki NishiwakiTeruki KobayashiSatoshi KomotoHiroaki SatoHajime KashimaTakuya KatoSatoru KikuchiHiroshi TazawaShunsuke KagawaYasuhiro ShirakawaHisataka KobayashiToshiyoshi FujiwaraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Ryoichi Katsube
Kazuhiro Noma
Toshiaki Ohara
Noriyuki Nishiwaki
Teruki Kobayashi
Satoshi Komoto
Hiroaki Sato
Hajime Kashima
Takuya Kato
Satoru Kikuchi
Hiroshi Tazawa
Shunsuke Kagawa
Yasuhiro Shirakawa
Hisataka Kobayashi
Toshiyoshi Fujiwara
Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
description Abstract Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate. We developed fibroblast activation protein (FAP)-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target CAFs (CAFs-targeted NIR-PIT: CAFs-PIT). Thus, we hypothesized that the control of CAFs could overcome the resistance to conventional chemotherapy in esophageal cancer (EC). In this study, we evaluated whether EC cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy are mediated by CAFs. Next, we assessed whether the resistance could be rescued by eliminating CAF stimulation by CAFs-PIT in vitro and in vivo. Cancer cells acquired chemoradiotherapy resistance via CAF stimulation in vitro and 5-fluorouracil (FU) resistance in CAF-coinoculated tumor models in vivo. CAF stimulation promoted the migration/invasion of cancer cells and a stem-like phenotype in vitro, which were rescued by elimination of CAF stimulation. CAFs-PIT had a highly selective effect on CAFs in vitro. Finally, CAF elimination by CAFs-PIT in vivo demonstrated that the combination of 5-FU and NIR-PIT succeeded in producing 70.9% tumor reduction, while 5-FU alone achieved only 13.3% reduction, suggesting the recovery of 5-FU sensitivity in CAF-rich tumors. In conclusion, CAFs-PIT could overcome therapeutic resistance via CAF elimination. The combined use of novel targeted CAFs-PIT with conventional anticancer treatments can be expected to provide a more effective and sensible treatment strategy.
format article
author Ryoichi Katsube
Kazuhiro Noma
Toshiaki Ohara
Noriyuki Nishiwaki
Teruki Kobayashi
Satoshi Komoto
Hiroaki Sato
Hajime Kashima
Takuya Kato
Satoru Kikuchi
Hiroshi Tazawa
Shunsuke Kagawa
Yasuhiro Shirakawa
Hisataka Kobayashi
Toshiyoshi Fujiwara
author_facet Ryoichi Katsube
Kazuhiro Noma
Toshiaki Ohara
Noriyuki Nishiwaki
Teruki Kobayashi
Satoshi Komoto
Hiroaki Sato
Hajime Kashima
Takuya Kato
Satoru Kikuchi
Hiroshi Tazawa
Shunsuke Kagawa
Yasuhiro Shirakawa
Hisataka Kobayashi
Toshiyoshi Fujiwara
author_sort Ryoichi Katsube
title Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
title_short Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
title_full Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
title_fullStr Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
title_full_unstemmed Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
title_sort fibroblast activation protein targeted near infrared photoimmunotherapy (nir pit) overcomes therapeutic resistance in human esophageal cancer
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/edf5fed397e64f0e8fa9e8ebc6976513
work_keys_str_mv AT ryoichikatsube fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT kazuhironoma fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT toshiakiohara fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT noriyukinishiwaki fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT terukikobayashi fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT satoshikomoto fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT hiroakisato fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT hajimekashima fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT takuyakato fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT satorukikuchi fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT hiroshitazawa fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT shunsukekagawa fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT yasuhiroshirakawa fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT hisatakakobayashi fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
AT toshiyoshifujiwara fibroblastactivationproteintargetednearinfraredphotoimmunotherapynirpitovercomestherapeuticresistanceinhumanesophagealcancer
_version_ 1718395199443435520